Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Journal for immunotherapy of cancer - 13 Jan 2026

Pesini Cecilia, Gil-Bellido Mario, S Millan Lorena, Oñate Carmen, Calvo-Pérez Adanays, Santiago Llipsy, Iglesias Eldris, Bernal Jorge Paúl, Araujo-Voces Miguel, Paz Artigas Laura, García-Martínez Laura, Roig Francisco J, Movilla Meno Nieves, Garcia-Aznar José Manuel, Menéndez-Jandula Bárbara, Olave María Teresa, Azaceta Reinares Gemma, Garrote Marta, Alvarez-Larrán Alberto, Gálvez Eva M, Sánchez Martínez Diego, Arias Maykel A, Pardo Julian, Ramirez-Labrada Ariel

Abstract excerpt

BACKGROUND: The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of...

Topics

Join the communities discussing this publication.

Bone Marrow Neoplasms
Calreticulin
Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Immunotherapy, Adoptive

Myeloproliferative Disorders

Receptors, Chimeric Antigen

Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41529908
DOI: 10.1136/jitc-2025-012706
PMCID: PMC12815064

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.PMID 41529908Read ↗

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.Semantic proximity Read ↗

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisSemantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.Semantic proximity Read ↗

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read ↗

Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.Semantic proximity Read ↗

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative NeoplasmsSemantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read ↗

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.Semantic proximity Read ↗

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.